IQVIA Study: Medisafe Digital Companion Dramatically Improves Medication Adherence and Extends Patients’ Therapy Persistence
In response to the challenge that Medisafe users are more inclined to be adherent with medication management, Medisafe created a study with IQVIA to measure the impact that digital companions can have on a chronically non-adherent patient population.
Medisafe’s study measured the impact of digital companions across three therapeutic areas: hypertension, major depressive disorder, and diabetes on over 4,000 patients.
Adherence was measured using the Medication Possession Ration (MPR) identifying patients for this study with a MPR of <0.8 (pre-index before using Medisafe). The study compared Medisafe users to a control group of non-Medisafe users who had been prescribed their specific medication for use between 2014 and 2017 to measure persistence.
Key Findings:
- More than 70% of patients became adherent
- Hypertension, diabetes and depression patients increased their median MPR to above 0.9 (out of a possible 1.0) after using Medisafe
- By month 12, hypertension and depression patients were 2-3x more likely to remain on therapy than the controls.
- By month 24, hypertension and depression patients were 6x more likely to remain on therapy than the controls.See all the results: Download the results:
See all the results (free, no registration required):
Build a smarter patient engagement strategy
See how Medisafe helps pharmaceutical teams activate patients, improve adherence, and measure outcomes across their portfolio.
